Fanconi anemia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Amar Morani (talk | contribs) No edit summary |
Amar Morani (talk | contribs) No edit summary |
||
Line 3: | Line 3: | ||
● '''Gene therapy''' – Gene therapy has the potential to improve bone marrow function in individuals with FA since the origin of bone marrow failure is deficiency of an FA gene function. Gene-corrected CD34+ stem cells from FA patients have been engrafted in immune-deficient mice, but successful clinical applications of gene therapy for FA have not yet been demonstrated.<ref name="pmid28801449">{{cite journal| author=Río P, Navarro S, Guenechea G, Sánchez-Domínguez R, Lamana ML, Yañez R et al.| title=Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients. | journal=Blood | year= 2017 | volume= 130 | issue= 13 | pages= 1535-1542 | pmid=28801449 | doi=10.1182/blood-2017-03-774174 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28801449 }}</ref> | ● '''Gene therapy''' – Gene therapy has the potential to improve bone marrow function in individuals with FA since the origin of bone marrow failure is deficiency of an FA gene function. Gene-corrected CD34+ stem cells from FA patients have been engrafted in immune-deficient mice, but successful clinical applications of gene therapy for FA have not yet been demonstrated.<ref name="pmid28801449">{{cite journal| author=Río P, Navarro S, Guenechea G, Sánchez-Domínguez R, Lamana ML, Yañez R et al.| title=Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients. | journal=Blood | year= 2017 | volume= 130 | issue= 13 | pages= 1535-1542 | pmid=28801449 | doi=10.1182/blood-2017-03-774174 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28801449 }}</ref> | ||
● Metformin – In a mouse model of FA (''FANCD''2 gene knockout), metformin produced modest increases in white blood cell (WBC) counts, hemoglobin levels, and platelet counts | ● Metformin – In a mouse model of FA (''FANCD''2 gene knockout), metformin produced modest increases in white blood cell (WBC) counts, hemoglobin levels, and platelet counts.<ref name="pmid27756748">{{cite journal| author=Zhang QS, Tang W, Deater M, Phan N, Marcogliese AN, Li H et al.| title=Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. | journal=Blood | year= 2016 | volume= 128 | issue= 24 | pages= 2774-2784 | pmid=27756748 | doi=10.1182/blood-2015-11-683490 | pmc=5159699 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27756748 }}</ref> There was also reduced p53-dependent tumor formation and a suggestion of decreased susceptibility to DNA damage. Metformin has not been evaluated in patients with FA. | ||
__NOTOC__ | __NOTOC__ |
Revision as of 19:40, 25 June 2018
Therapies under development
● Gene therapy – Gene therapy has the potential to improve bone marrow function in individuals with FA since the origin of bone marrow failure is deficiency of an FA gene function. Gene-corrected CD34+ stem cells from FA patients have been engrafted in immune-deficient mice, but successful clinical applications of gene therapy for FA have not yet been demonstrated.[1]
● Metformin – In a mouse model of FA (FANCD2 gene knockout), metformin produced modest increases in white blood cell (WBC) counts, hemoglobin levels, and platelet counts.[2] There was also reduced p53-dependent tumor formation and a suggestion of decreased susceptibility to DNA damage. Metformin has not been evaluated in patients with FA.
References
- ↑ Río P, Navarro S, Guenechea G, Sánchez-Domínguez R, Lamana ML, Yañez R; et al. (2017). "Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients". Blood. 130 (13): 1535–1542. doi:10.1182/blood-2017-03-774174. PMID 28801449.
- ↑ Zhang QS, Tang W, Deater M, Phan N, Marcogliese AN, Li H; et al. (2016). "Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice". Blood. 128 (24): 2774–2784. doi:10.1182/blood-2015-11-683490. PMC 5159699. PMID 27756748.